As of 11 November 2026.
A medical device made outside Europe and sold in the European Union and in Great Britain: who owes what? The manufacturer owes the whole device. In the Union it can only sell through one authorised representative, who is jointly liable with it. The importer has four checks of its own and puts its name on the device. In Great Britain a UK Responsible Person registers the device and can be prosecuted as the person placing it on the market. Two dates fall in the next four weeks: 28 November and 9 December 2026.
One device, four companies
Meridian Life Sciences is a fictitious group we use for our examples. Its American company makes a software-driven class IIa device, certified under Regulation (EU) 2017/745, the Medical Devices Regulation. A German company of the group is both its authorised representative and its importer in the Union. A British company is its UK Responsible Person and its importer in Great Britain.
Four roles, three companies, one device. Each role carries duties the others do not, and a company that holds two roles carries both sets.
The same device, read for each role
The first three columns come from the consolidated Regulation, the fourth from the UK Medical Devices Regulations 2002 as amended. Each cell names its provision.
| Duty | Manufacturer (EU rules) | EU authorised representative | EU importer | UK Responsible Person |
|---|---|---|---|---|
| Registration | Registers itself and the device before placing it on the market (Art. 29 and 31). From outside the Union, it can only register with an active authorised representative. | Registers itself (Art. 31). Verifies the manufacturer's registrations (Art. 11(3)(c)). | Registers itself (Art. 31). Verifies that the device is registered and adds its own details (Art. 13(4)). Checks the entry within two weeks of placing (Art. 30(3)). | Registers the devices with the MHRA, with written evidence of the manufacturer's authority (reg. 7A(2)). |
| Technical documentation and declaration of conformity | Draws them up and keeps them up to date (Art. 10(4) and (6)). | Verifies that they have been drawn up and keeps a copy (Art. 11(3)(a) and (b)). | Verifies the CE marking and the declaration (Art. 13(2)(a)). Keeps a copy of the declaration (Art. 13(9)). | Ensures that they have been drawn up and keeps copies available for inspection (reg. 7A(3)(a) and (b)). |
| Checks before the device is placed on the market | Ensures that design and manufacture conform (Art. 10(1)). | None beyond the verification above. | Four checks: CE marking and declaration, manufacturer and representative identified, labelling and instructions, a UDI assigned (Art. 13(2)). | Ensures that the conformity assessment has been carried out (reg. 7A(3)(a)). |
| Name on the device | Its name and address on the label (Annex I, 23.2(c)). | Its name and address on the label, put there by the manufacturer (Annex I, 23.2(d)). | Its own name and address on the device, its packaging or an accompanying document (Art. 13(3)). | Not required on a CE marked device, unless it also bears the UKCA marking (MHRA guidance). |
| Complaints | Records incidents and corrective actions in its quality system (Art. 10(9) and (13)). | Informs the manufacturer immediately (Art. 11(3)(g)). | Keeps a register of complaints, non-conforming devices, recalls and withdrawals (Art. 13(6)). Forwards reports immediately (Art. 13(8)). | Informs the manufacturer immediately (reg. 7A(3)(g)). |
| Serious incidents | Reports within 15 days, 2 days for a serious public health threat, 10 days for a death or an unanticipated serious deterioration in health (Art. 87(3) to (5)). | Does not report. Forwards to the manufacturer. | Does not report. Forwards, and informs the authorities itself where the device presents a serious risk (Art. 13(7)). | Does not report. The manufacturer reports within the same 15, 2 and 10 days and names the UK Responsible Person in the report (reg. 44ZH). |
| Records | 10 years after the last device, 15 years for implantable devices (Art. 10(8)). | The same period (Art. 11(3)(b)). | The same period (Art. 13(9)). | Surveillance documents: the longer of the surveillance period and 10 years, 15 for implantable devices (reg. 44ZQ). |
| Liability | Must hold sufficient financial coverage for its potential liability (Art. 10(16)). | Jointly and severally liable with a manufacturer outside the Union that has not complied with Article 10 (Art. 11(5)). | Becomes the manufacturer if it sells the device under its own name, changes its intended purpose or modifies it (Art. 16(1)). | May be proceeded against as a person placing the device on the market (reg. 60(3)). |
| Compliance person | A person responsible for regulatory compliance within the organisation (Art. 15(1)). | One permanently and continuously at its disposal (Art. 15(6)). | None required by the Regulation. | None required by regulation 7A. |
See the same reading for one of your own companies. Request a free trial and give us one entity, its country and its sector. We will send you a one-page diagnostic of the texts that affect it over the next twelve months, each with its official source. Request a free trial
Three things the table makes visible
The authorised representative is not a letterbox. A device from a manufacturer outside the Union "may only be placed on the Union market if the manufacturer designates a sole authorised representative" (Art. 11(1)). The mandate must be accepted in writing. It cannot hand over the manufacturer's core obligations, which Article 11(4) lists. And if the manufacturer has not complied with Article 10, the representative is liable for defective devices "on the same basis as, and jointly and severally with, the manufacturer". For the German company of our example, that exposure is the real content of the role.
An importer can become the manufacturer without noticing. Selling the device under its own name, changing its intended purpose or modifying it puts the manufacturer's obligations on the importer (Art. 16(1)). Translating the label is not a modification. It still requires a notice to the manufacturer and to the authority at least 28 days before the relabelled device is made available, and a notified body certificate for the importer's quality system (Art. 16(2) to (4)).
In Great Britain the verb is "ensure". The EU representative verifies that the documentation has been drawn up. The UK Responsible Person must ensure it. Since June 2025 the British post-market surveillance rules add two duties it shares with the manufacturer: hand the surveillance plan and reports to the regulator within 3 working days of a request, and keep the documents for the period in the table. An importer or distributor in Great Britain does not need a UK Responsible Person of its own, and nothing prevents an importer from being one.
Two dates in the next four weeks
28 November 2026: devices already on the market must be in EUDAMED. Four modules of the European database have been mandatory since 28 May 2026: actor registration, device registration, notified bodies and certificates, market surveillance. The Commission's timeline gives 28 November 2026 as the deadline to register devices that were already on the market before 28 May 2026 and are still being placed on it. The vigilance module is still in development, so incident reports do not go through EUDAMED yet. A manufacturer outside the Union cannot register at all without an active authorised representative.
9 December 2026: a new liability for the importer and the representative. Directive (EU) 2024/2853 on liability for defective products applies to products placed on the market after 9 December 2026. Where the manufacturer is established outside the Union, Article 8(1)(c) makes the importer and the manufacturer's authorised representative liable, without prejudice to the liability of the manufacturer. It applies through national law. In our example the German company holds both roles.
What is not law yet
The Commission's proposal to revise the Regulation, COM(2025) 1023, is at committee stage in the European Parliament. Nothing in the table changes until it is adopted.
In Great Britain, the government confirmed on 21 October 2026 that it will continue to accept CE marked devices on a long-term basis. The law has not changed yet. Regulation 1ZA still ends the acceptance of devices certified under the former directives on 30 June 2028, and of devices certified under the Regulation on 30 June 2030.
Two neighbours, briefly. Northern Ireland applies the EU Regulation. Switzerland requires a manufacturer outside the country to appoint an authorised representative established there, on the model of Article 11, and since 1 July 2026 the device identifier is registered with Swissmedic.
What this article does not settle
We did not establish which incident reporting deadlines apply in practice until the vigilance module of EUDAMED is in use: the table gives the deadlines of the Regulation itself. We did not read how each Member State transposes the liability directive. We did not check whether a company holding two roles receives one registration number or two. And the British surveillance rules entered into force in June 2025: the regulator says 16 June, the official legislation site annotates 17 June.
Official texts read
Read on 11 November 2026 on EUR-Lex, the European Commission's site, legislation.gov.uk, GOV.UK and Fedlex.
- Regulation (EU) 2017/745, consolidated version of 9 November 2026: Articles 10 to 16, 27 to 31, 87, 120 and 123, Annex I.
- Commission Decision (EU) 2025/2371 of 26 November 2025 on the functionality of EUDAMED.
- European Commission, EUDAMED overview and actor registration.
- Directive (EU) 2024/2853 on liability for defective products: Article 8.
- European Parliament, procedure 2025/0404(COD).
- The Medical Devices Regulations 2002 (SI 2002/618): regulations 1ZA, 7A, 19C, 44ZH, 44ZQ and 60. SI 2024/1368 on post-market surveillance.
- MHRA, Regulating medical devices in the UK and Register medical devices to place on the market.
- UK government, announcement of 21 October 2026 on CE marked devices.
- Swiss Medical Devices Ordinance (SR 812.213), version of 1 July 2026: Articles 17, 51 and 52.


